Literature DB >> 31342874

Trypanosoma cruzi infection in a zoo-housed red panda in Kansas.

Gail L Huckins1,2,3, David Eshar1,2,3, Diana Schwartz1,2,3, Mark Morton1,2,3, Brian H Herrin1,2,3, Argine Cerezo1,2,3, Michael J Yabsley1,2,3, Sarah M Schneider1,2,3.   

Abstract

A 9-y-old, zoo-housed, male red panda (Ailurus fulgens) became progressively lethargic and inappetent over a 1-wk period. Physical examination was unremarkable. A complete blood count showed mild normocytic, normochromic, non-regenerative anemia with the presence of trypomastigote organisms, consistent with a Trypanosoma sp. The organism was confirmed later as Trypanosoma cruzi lineage TcI via PCR and genome sequencing. The panda was initially treated supportively; however, its clinical status within 24 h from presentation deteriorated, and euthanasia was elected. Autopsy showed severe systemic T. cruzi infection with the presence of amastigotes in the heart, brain, peripheral nerves, skeletal muscles, tongue, liver, and testes. We used genome sequencing and serology in identifying the agent.

Entities:  

Keywords:  Chagas disease; genetic characterization

Year:  2019        PMID: 31342874      PMCID: PMC6727118          DOI: 10.1177/1040638719865926

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  2 in total

1.  Autochthonous Chagas Disease in the United States: How Are People Getting Infected?

Authors:  Norman L Beatty; Stephen A Klotz
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

2.  Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates.

Authors:  Angel M Padilla; Wei Wang; Robert T Jacobs; Rick L Tarleton; Tsutomu Akama; David S Carter; Eric Easom; Yvonne Freund; Jason S Halladay; Yang Liu; Sarah A Hamer; Carolyn L Hodo; Gregory K Wilkerson; Dylan Orr; Brooke White; Arlene George; Huifeng Shen; Yiru Jin; Michael Zhuo Wang; Susanna Tse
Journal:  Nat Microbiol       Date:  2022-09-05       Impact factor: 30.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.